메뉴 건너뛰기




Volumn 109, Issue 4, 2002, Pages 489-502

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa

Author keywords

Bromocriptine; Drug therapy; Parkinson's disease; Ropinirole

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE; SELEGILINE;

EID: 0036209516     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200040     Document Type: Article
Times cited : (61)

References (32)
  • 13
    • 0030726156 scopus 로고    scopus 로고
    • Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
    • International Pramipexole-Bromocriptine Study Group
    • (1997) Neurology , vol.49 , pp. 1060-1065
    • Guttman, M.1
  • 18
    • 0029269229 scopus 로고
    • The rationale for the use of dopamine agonists in Parkinson's disease
    • (1995) Neurology , vol.45 , Issue.SUPPL. 3
    • Jenner, P.1
  • 27
    • 0027363740 scopus 로고
    • A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease
    • (1993) Mov Disord , vol.8 , Issue.SUPPL. 1
    • Olanow, C.W.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.